FINWIRES · TerminalLIVE
FINWIRES

澳新银行称,新西兰4月份商业信心转为负值

By

-- 澳新银行研究部周四发布的报告显示,由于通胀指标持续走高,新西兰4月份的商业信心指数转为负值,从上月的32.5降至-10.6。 该研究机构表示:“面对如此巨大的成本冲击,企业对其业务活动和盈利前景感到担忧是可以理解的。”报告还指出,目前经营企业仍面临“非常严峻的挑战”。 然而,4月份的-10.6高于3月下旬调查的平均-22.5,表明至少部分最初的信心冲击已经消退。 澳新银行研究部表示,4月份通胀预期从3月份的3.1%升至3.8%,但价格意向并未进一步上升,这对新西兰储备银行来说应该是一个令人安心的消息。 调查中衡量GDP的最佳指标——已报告的过去经济活动——在4月份保持稳定。

Related Articles

Asia

Sanhua Intelligent Controls Q1 Profit Up 3%; Shares Rise 5%

Zhejiang Sanhua Intelligent Controls (SHE:002050) posted first-quarter attributable net profit of 927.6 million yuan, up 2.7% from 903.4 million yuan the previous year.Earnings per share declined to 0.22 yuan from 0.24 yuan, according to a Thursday filing with the Shenzhen bourse.Operating revenue climbed 1.4% year over year to 7.77 billion yuan from 7.67 billion yuan.Shares of the refrigeration and air-conditioning components maker were up 5% in recent trade.

$SHE:002050
Asia

Singapore's Total Employment Expands in Q1

Singapore's total employment grew by 5,000 during the first quarter of the year, compared to 2,300 a year earlier, marking the 18th consecutive quarter of job growth, according to preliminary data from the Ministry of Manpower released Thursday.Despite the year-on-year growth, employment was down from the 17,700 growth in the previous quarter, mainly due to broad-based weakening in the labor market.Overall, unemployment rates edged up to 2.1% in March, compared to 2.0% in December 2025.Retrenchments remained low at 1.5 per 1,000 employees in Q1, unchanged from Q4, 2025.The ministry expects labor market to remain tight and expand in the second quarter. However, the share of firms expecting to hire in the next three months fell to 44.6% in March, compared to 54.6% in February.

$^STI
Asia

Clarity Pharmaceuticals to Start Registrational Phase 3 Trial in Neuroendocrine Tumors After US FDA Meeting

Clarity Pharmaceuticals (ASX:CU6) will start a registrational phase 3 trial of copper-64-SARTATE in neuroendocrine tumors, following a successful end-of-phase meeting with the US Food and Drug Administration (FDA), according to a Thursday Australian bourse filing.The company plans to recruit around 70 participants for the trial.Clarity is also conducting recruitment for its registrational phase 3 positron emission tomography imaging trial of participants with high-risk prostate cancer prior to radical prostatectomy using copper-64-SAR-bisPSMA in the US and Australia, per the filing. It plans to recruit around 383 participants.The trial will assess the diagnostic performance of copper-64-SAR-bisPSMA positron emission tomography in detecting prostate cancer within the pelvic lymph nodes, the filing said.Clarity Pharmaceuticals' shares fell nearly 2% in recent trading on Thursday.

$ASX:CU6